BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

543 related articles for article (PubMed ID: 16130178)

  • 21. Highly potent 1-aminocyclohexane-1-carboxylic acid substituted V2 agonists of arginine vasopressin.
    Kowalczyk W; Prahl A; Derdowska I; Dawidowska O; Slaninová J; Lammek B
    J Med Chem; 2004 Nov; 47(24):6020-4. PubMed ID: 15537356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [1-deamino-4-cyclohexylalanine] arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors.
    Derick S; Cheng LL; Voirol MJ; Stoev S; Giacomini M; Wo NC; Szeto HH; Ben Mimoun M; Andres M; Gaillard RC; Guillon G; Manning M
    Endocrinology; 2002 Dec; 143(12):4655-64. PubMed ID: 12446593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Iodination of vasopressin analogues with agonistic and antagonistic properties: effects on biological properties and affinity for vascular and renal vasopressin receptors.
    Jard S; Lombard C; Seyer R; Aumelas A; Manning M; Sawyer WH
    Mol Pharmacol; 1987 Sep; 32(3):369-75. PubMed ID: 2959851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analogues of neurohypophyseal hormones, oxytocin and arginine vasopressin, conformationally restricted in the N-terminal part of the molecule.
    Kowalczyk W; Prahl A; Derdowska I; Sobolewski D; Olejnik J; Zabrocki J; Borovicková L; Slaninová J; Lammek B
    J Med Chem; 2006 Mar; 49(6):2016-21. PubMed ID: 16539389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel analogues of arginine vasopressin containing alpha-2-indanylglycine enantiomers in position 2.
    Kwiatkowska A; Sleszyńska M; Derdowska I; Prahl A; Sobolewski D; Borovicková L; Slaninová J; Lammek B
    J Pept Sci; 2010 Jan; 16(1):15-20. PubMed ID: 19924728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells.
    Tsukada J; Tahara A; Tomura Y; Wada Ki ; Kusayama T; Ishii N; Yatsu T; Uchida W; Taniguchi N; Tanaka A
    Br J Pharmacol; 2001 Jul; 133(5):746-54. PubMed ID: 11429400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor.
    Chan WY; Wo NC; Cheng LL; Manning M
    J Pharmacol Exp Ther; 1996 May; 277(2):999-1003. PubMed ID: 8627583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors.
    Tahara A; Tsukada J; Tomura Y; Kusayama T; Wada K; Ishii N; Taniguchi N; Suzuki T; Yatsu T; Uchida W; Shibasaki M
    Pharmacol Res; 2005 Mar; 51(3):275-81. PubMed ID: 15661579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of uPA release in human peripheral blood lymphocytes by [deamino-Cysl,D-Arg8]-vasopressin (dDAVP).
    Yamaguchi Y; Yamada K; Suzuki T; Wu YP; Kita K; Takahashi S; Ichinose M; Suzuki N
    Am J Physiol Endocrinol Metab; 2004 Nov; 287(5):E970-6. PubMed ID: 15198931
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potent antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid),2-D- phenylalanine,4-valine]arginine-vasopressin at position 4.
    Manning M; Olma A; Klis WA; Seto J; Sawyer WH
    J Med Chem; 1983 Nov; 26(11):1607-13. PubMed ID: 6631916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological characterization of RWJ-676070, a dual vasopressin V(1A)/V(2) receptor antagonist.
    Gunnet JW; Wines P; Xiang M; Rybczynski P; Andrade-Gordon P; de Garavilla L; Parry TJ; Cheung WM; Minor L; Demarest KT; Maryanoff BE; Damiano BP
    Eur J Pharmacol; 2008 Aug; 590(1-3):333-42. PubMed ID: 18599033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and some pharmacological properties of 18 potent O-alkyltyrosine-substituted antagonists of the vasopressor responses to arginine-vasopressin.
    Manning M; Lammek B; Bankowski K; Seto J; Sawyer WH
    J Med Chem; 1985 Oct; 28(10):1485-91. PubMed ID: 4045923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel strategies for the design of receptor-selective vasopressin analogues: Aib-substitution and retro-inverso transformation.
    Howl J; Prochazka Z; Wheatley M; Slaninová J
    Br J Pharmacol; 1999 Oct; 128(3):647-52. PubMed ID: 10516644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potent and selective antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-beta,beta-pentamethylenepropionic acid),2-D-isoleucine,4- valine]arginine-vasopressin at position 4.
    Manning M; Nawrocka E; Misicka A; Olma A; Klis WA; Seto J; Sawyer WH
    J Med Chem; 1984 Apr; 27(4):423-9. PubMed ID: 6708045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analogues of arginine vasopressin modified in position 2 and 3 with conformationally constrained dipeptide fragments.
    Łempicka E; Derdowska I; Kowalczyk W; Dawidowska O; Prahl A; Janecki M; Jasiński T; Trzeciak HI; Lammek B
    J Pept Sci; 2005 Feb; 11(2):91-6. PubMed ID: 15635636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New, potent, selective, and short-acting peptidic V1a receptor agonists.
    Wisniewski K; Galyean R; Tariga H; Alagarsamy S; Croston G; Heitzmann J; Kohan A; Wisniewska H; Laporte R; Rivière PJ; Schteingart CD
    J Med Chem; 2011 Jul; 54(13):4388-98. PubMed ID: 21688787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of receptors mediating contraction of the rat isolated small mesenteric artery and aorta to arginine vasopressin and oxytocin.
    Stam WB; Van der Graaf PH; Saxena PR
    Br J Pharmacol; 1998 Oct; 125(4):865-73. PubMed ID: 9831926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of bulky 3,3'-diphenylalanine enantiomers replacing position 2 of AVP analogues on their conformations: NMR and molecular modeling studies.
    Sikorska E; Kwiatkowska A; Sobolewski D; Slusarz R; Slusarz MJ
    Eur J Med Chem; 2010 Sep; 45(9):4065-73. PubMed ID: 20580135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Agonist selectivity in the oxytocin/vasopressin receptor family: new insights and challenges.
    Chini B; Manning M
    Biochem Soc Trans; 2007 Aug; 35(Pt 4):737-41. PubMed ID: 17635137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel sst(4)-selective somatostatin (SRIF) agonists. 2. Analogues with beta-methyl-3-(2-naphthyl)alanine substitutions at position 8.
    Erchegyi J; Penke B; Simon L; Michaelson S; Wenger S; Waser B; Cescato R; Schaer JC; Reubi JC; Rivier J
    J Med Chem; 2003 Dec; 46(26):5587-96. PubMed ID: 14667213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.